Suprefort
Suprefort is a Khavinson short peptide bioregulator for the pancreas. Proposed to support pancreatic cell gene regulation and beta cell function in aging models. Used in anti-aging research involving metabolic aging and pancreatic reserve.
Community Rating
No ratings yet
Compound Profile
Suprefort
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Suprefort is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Proposed to support pancreatic beta cell gene expression and insulin-secretion capacity in aging
- May address age-related decline in pancreatic functional reserve and glucose tolerance
- Complement to metabolic anti-aging approaches (alongside MOTS-c, NAD+ precursors)
- Suprefort is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Proposed to support pancreatic beta cell gene expression and insulin-secretion capacity in aging
- May address age-related decline in pancreatic functional reserve and glucose tolerance
- Complement to metabolic anti-aging approaches (alongside MOTS-c, NAD+ precursors)
- Targeted at one of the most clinically relevant aging endpoints: age-related glucose intolerance and T2D risk
In Plain English
Simple summaryThink of Suprefort as a signalling molecule your body already recognises, it doesn't introduce anything foreign, it tells specific cells to do things they're already capable of doing, just more efficiently.
- Proposed to support pancreatic beta cell gene expression and insulin-secretion capacity in aging
- May address age-related decline in pancreatic functional reserve and glucose tolerance
- Complement to metabolic anti-aging approaches
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Suprefort?
Tap any underlined term for an instant definition.
Suprefort is a peptide bioregulator developed by Professor Khavinson's research group, derived from pancreatic tissue, targeting pancreatic aging and the age-related decline in glucose metabolism.
The pancreas undergoes substantial functional changes with aging: beta cell mass and insulin-secretory capacity decline, first-phase insulin secretion becomes blunted (an early marker of T2D development), and glucagon suppression after meals is impaired. These changes contribute directly to the near-universal age-related increase in fasting glucose and the dramatically increased T2D risk after age 65.
In the Khavinson bioregulator framework, Suprefort contains short regulatory peptides from pancreatic tissue that are proposed to support gene expression in pancreatic islet cells — primarily beta cells (insulin-secreting) but potentially also ductal cells (pancreatic stem cell niche) and acinar cells (exocrine function).
Research from the Khavinson group has included studies in animal models of diabetes showing improved glucose tolerance after treatment with pancreatic tissue peptide bioregulators, and clinical observational studies in elderly patients showing improvements in glucose metabolism markers.
Suprefort occupies a unique niche in the Khavinson bioregulator system because the pancreas is both an exocrine and endocrine organ — its anti-aging relevance spans digestive function (exocrine enzyme secretion) and metabolic regulation (insulin/glucagon). It is often combined with metabolic anti-aging interventions (Epithalon, MOTS-c, NAD+ precursors) in comprehensive longevity protocols.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Suprefort. See all Metabolic & Weight peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Oral capsule. Part of comprehensive metabolic aging and pancreatic reserve protocols.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Suprefort, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Suprefort has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: proposed to support pancreatic beta cell gene expression and insulin-secretion capacity in aging.
The most commonly reported side effect in research subjects is minimal adverse effects in the khavinson program. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.